Modulation of GITR for cancer immunotherapy

Current Opinion in Immunology

Volumn 24, Issue 2, 2012, Pages 217-224

  Schaer, David A ^a   Murphy, Judith T ^a,b   Wolchok, Jedd D ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; DNA VACCINE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4-1BB; MONOCLONAL ANTIBODY DTA-1; MONOCLONAL ANTIBODY OX-40; UNCLASSIFIED DRUG;

B LYMPHOCYTE; BASOPHIL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON TUMOR; DRUG TARGETING; EOSINOPHIL; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSTIMULATION; LIVER DISEASE; LYMPHOMA; MACROPHAGE; MAST CELL; MELANOMA; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 84858787656     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.12.011     Document Type: Review

References (67)

1. Nocentini G., Giunchi L., Ronchetti S., Krausz L.T., Bartoli A., Moraca R., Migliorati G., Riccardi C. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci U S A 1997, 94:6216-6221.
2. Kwon B., Yu K.Y., Ni J., Yu G.L., Jang I.K., Kim Y.J., Xing L., Liu D., Wang S.X., Kwon B.S. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 1999, 274:6056-6061.
3. Gurney A.L., Marsters S.A., Huang R.M., Pitti R.M., Mark D.T., Baldwin D.T., Gray A.M., Dowd A.D., Brush A.D., Heldens A.D., et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 1999, 9:215-218.
4. Valzasina B., Guiducci C., Dislich H., Killeen N., Weinberg A.D., Colombo M.P. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005, 105:2845-2851.
5. Ronchetti S., Zollo O., Bruscoli S., Agostini M., Bianchini R., Nocentini G., Ayroldi E., Riccardi C. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 2004, 34:613-622.
6. Pollok K., Kim Y., Zhou Z., Hurtado J., Kim K., Pickard R., Kwon B. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993, 150:771-781.
7. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010, 28:57-78.
8. Tone M., Tone Y., Adams E., Yates S.F., Frewin M.R., Cobbold S.P., Waldmann H. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A 2003, 100:15059-15064.
9. Dawicki W., Watts T.H. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur J Immunol 2004, 34:743-751.
10. Ronchetti S., Nocentini G., Riccardi C., Pandolfi P.P. Role of GITR in activation response of T lymphocytes. Blood 2002, 100:350-352.
11. Snell L.M., Lin G.H.Y., McPherson A.J., Moraes T.J., Watts T.H. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev 2011, 244:197-217.
12. Suvas S., Kim B., Sarangi P.P., Tone M., Waldmann H., Rouse B.T. In vivo kinetics of GITR and GITR ligand expression and their functional significance in regulating viral immunopathology. J Virol 2005, 79:11935-11942.
13. Nocentini G., Riccardi C. GITR: A Modulator of Immune Response and Inflammation Therapeutic Targets of the TNF Superfamily 2009, 156-173. Springer, New York. I.S. Grewal (Ed.).
14. Chattopadhyay K., Ramagopal U.A., Brenowitz M., Nathenson S.G., Almo S.C. Evolution of GITRL immune function: murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily. Proc Natl Acad Sci U S A 2008, 105:635-640.
15. Zhou Z., Tone Y., Song X., Furuuchi K., Lear J.D., Waldmann H., Tone M., Greene M.I., Murali R. Structural basis for ligand-mediated mouse GITR activation. Proc Natl Acad Sci U S A 2008, 105:641-645.
16. Kanamaru F., Youngnak P., Hashiguchi M., Nishioka T., Takahashi T., Sakaguchi S., Ishikawa I., Azuma M. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol 2004, 172:7306-7314.
17. Kohm A.P., Williams J.S., Miller S.D. Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis. J Immunol 2004, 172:4686-4690.
18. Muriglan S.J., Ramirez-Montagut T., Alpdogan O., Van Huystee T.W., Eng J.M., Hubbard V.M., Kochman A.A., Tjoe K.H., Riccardi C., Pandolfi P.P., et al. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease. J Exp Med 2004, 200:149-157.
19. Esparza E.M., Arch R.H. Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation. J Immunol 2005, 174:7869-7874.
20. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
21. Snell L.M., McPherson A.J., Lin G.H.Y., Sakaguchi S., Pandolfi P.P., Riccardi C., Watts T.H. CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol 2010, 185:7223-7234.
22. Lin G.H.Y., Sedgmen B.J., Moraes T.J., Snell L.M., Topham D.J., Watts T.H. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol 2009, 182:934-947.
23. van der Werf N., Redpath S.A., Phythian-Adams A.T., Azuma M., Allen J.E., Maizels R.M., MacDonald A.S., Taylor M.D. Th2 responses to helminth parasites can be therapeutically enhanced by, but are not dependent upon, GITR-GITR ligand costimulation in vivo. J Immunol 2011, 187:1411-1420.
24. Cuzzocrea S., Ayroldi E., Di Paola R., Agostini M., Mazzon E., Bruscoli S., Genovese T., Ronchetti S., Caputi A.P., Riccardi C. Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis. FASEB J 2005, 19:1253-1265.
25. Cuzzocrea S., Nocentini G., Di Paola R., Agostini M., Mazzon E., Ronchetti S., Crisafulli C., Esposito E., Caputi A.P., Riccardi C. Proinflammatory role of glucocorticoid-induced TNF receptor-related gene in acute lung inflammation. J Immunol 2006, 177:631-641.
26. Cuzzocrea S., Nocentini G., Di Paola R., Mazzon E., Ronchetti S., Genovese T., Muia C., Caputi A.P., Riccardi C. Glucocorticoid-induced TNF receptor family gene (GITR) knockout mice exhibit a resistance to splanchnic artery occlusion (SAO) shock. J Leukoc Biol 2004, 76:933-940.
27. Cuzzocrea S., Ronchetti S., Genovese T., Mazzon E., Agostini M., Di Paola R., Esposito E., Muia C., Nocentini G., Riccardi C. Genetic and pharmacological inhibition of GITR-GITRL interaction reduces chronic lung injury induced by bleomycin instillation. FASEB J 2007, 21:117-129.
28. Galuppo M., Nocentini G., Mazzon E., Ronchetti S., Esposito E., Riccardi L., Di Paola R., Bruscoli S., Riccardi C., Cuzzocrea S. GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan. Shock 2011, 36:263-271.
29. Galuppo M., Nocentini G., Mazzon E., Ronchetti S., Esposito E., Riccardi L., Sportoletti P., Di Paola R., Bruscoli S., Riccardi C., et al. The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice. Br J Pharmacol 2011, 162:1186-1201.
30. Santucci L., Agostini M., Bruscoli S., Mencarelli A., Ronchetti S., Ayroldi E., Morelli A., Baldoni M., Riccardi C. GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice. Gut 2007, 56:52-60.
31. Placke T., Kopp H.G., Salih H.R. Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin Dev Immunol 2010, 2010:p239083.
32. Kohrt H.E., Houot R., Goldstein M.J., Weiskopf K., Alizadeh A.A., Brody J., Muller A., Pachynski R., Czerwinski D., Coutre S., et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011, 117:2423-2432.
33. Hanabuchi S., Watanabe N., Wang Y.H., Ito T., Shaw J., Cao W., Qin F.X., Liu Y.J. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 2006, 107:3617-3623.
34. Liu B., Li Z., Mahesh S.P., Pantanelli S., Hwang F.S., Siu W.O., Nussenblatt R.B. Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis. J Biol Chem 2008, 283:8202-8210.
35. Baltz K.M., Krusch M., Bringmann A., Brossart P., Mayer F., Kloss M., Baessler T., Kumbier I., Peterfi A., Kupka S., et al. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007, 21:2442-2454.
36. Baessler T., Charton J.E., Schmiedel B.J., Grunebach F., Krusch M., Wacker A., Rammensee H.G., Salih H.R. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010, 115:3058-3069.
37. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002, 3:135-142.
38. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., Byrne M.C. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
39. Stephens G.L., McHugh R.S., Whitters M.J., Young D.A., Luxenberg D., Carreno B.M., Collins M., Shevach E.M. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 2004, 173:5008-5020.
40. North R.J. Down-regulation of the antitumor immune response. Adv Cancer Res 1985, 45:1-43.
41. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004, 200:771-782.
42. Cohen A.D., Schaer D.A., Liu C., Li Y., Hirschhorn-Cymmerman D., Kim S.C., Diab A., Rizzuto G., Duan F., Perales M.A., et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010, 5:pe10436.
43. Ko K., Yamazaki S., Nakamura K., Nishioka T., Hirota K., Yamaguchi T., Shimizu J., Nomura T., Chiba T., Sakaguchi S. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005, 202:885-891.
44. Houot R., Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood 2009, 113:3546-3552.
45. Zhou P., L'Italien L., Hodges D., Schebye X.M. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 2007, 179:7365-7375.
46. Boczkowski D., Lee J., Pruitt S., Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther 2009, 16:900-911.
47. Nishikawa H., Kato T., Hirayama M., Orito Y., Sato E., Harada N., Gnjatic S., Old L.J., Shiku H. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 2008, 68:5948-5954.
48. Cohen A.D., Diab A., Perales M.A., Wolchok J.D., Rizzuto G., Merghoub T., Huggins D., Liu C., Turk M.J., Restifo N.P., et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006, 66:4904-4912.
49. Hoffmann C., Stanke J., Kaufmann A.M., Loddenkemper C., Schneider A., Cichon G. Combining T-cell vaccination and application of agonistic anti-GITR mAb (DTA-1) induces complete eradication of HPV oncogene expressing tumors in mice. J Immunother 2010, 33:136-145.
50. Mitsui J., Nishikawa H., Muraoka D., Wang L., Noguchi T., Sato E., Kondo S., Allison J.P., Sakaguchi S., Old L.J., et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010, 16:2781-2791.
51. Imai N., Ikeda H., Tawara I., Wang L., Nishikawa H., Kato T., Shiku H. Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression. Cancer Sci 2009, 100:1317-1325.
52. Pruitt S.K., Boczkowski D., de Rosa N., Haley N.R., Morse M.A., Tyler D.S., Dannull J., Nair S. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol 2011, (Epub online September 9, 2011).
53. Ramirez-Montagut T., Chow A., Hirschhorn-Cymerman D., Terwey T.H., Kochman A.A., Lu S., Miles R.C., Sakaguchi S., Houghton A.N., van den Brink M.R. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006, 176:6434-6442.
54. Zhou P., Qiu J., L'Italien L., Gu D., Hodges D., Chao C.C., Schebye X.M. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. J Immunother 2010, 33:789-797.
55. Côté A.L., Zhang P., O'Sullivan J.A., Jacobs V.L., Clemis C.R., Sakaguchi S., Guevara-Patiño J.A., Turk M.J. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol 2011, 186:275-283.
56. Curran M.A., Kim M., Montalvo W., Al-Shamkhani A., Allison J.P. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011, 6:pe19499.
57. Hirschhorn-Cymerman D., Rizzuto G.A., Merghoub T., Cohen A.D., Avogadri F., Lesokhin A.M., Weinberg A.D., Wolchok J.D., Houghton A.N. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009, 206:1103-1116.
58. Piconese S., Valzasina B., Colombo M.P. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008, 205:825-839.
59. Quezada S.A., Peggs K.S., Curran M.A., Allison J.P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006, 116:1935-1945.
60. Coe D., Begom S., Addey C., White M., Dyson J., Chai J.-G. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 2010, 59:1367-1377.
61. Rosenzwieg M., Ponte J., Apostolou I., Doty D., Guild J., Slavonic M., Ponath P., Vaikus L. Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR. J Clin Oncol 2010, 28(Suppl.):pe13028.
62. Tolerx Inc. Agonistic antibodies to human glucocorticoid-induced tumor necrosis factor receptor as potential stimulators of T cell immunity for the treatment of cancer and viral infections. Expert Opin Ther Patents 2007, 17:567-575.
63. Ascierto P.A., Simeone E., Sznol M., Fu Y.-X., Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010, 37:508-516.
64. Weinberg A.D., Morris N.P., Kovacsovics-Bankowski M., Urba W.J., Curti B.D. Science gone translational: the OX40 agonist story. Immunol Rev 2011, 244:218-231.
65. You S., Poulton L., Cobbold S., Liu C.P., Rosenzweig M., Ringler D., Lee W.H., Segovia B., Bach J.F., Waldmann H., et al. Key role of the GITR/GITR ligand pathway in the development of murine autoimmune diabetes: a potential therapeutic target. PLoS One 2009, 4:pe7848.
66. Uraushihara K., Kanai T., Ko K., Totsuka T., Makita S., Iiyama R., Nakamura T., Watanabe M. Regulation of murine inflammatory bowel disease by CD25+ and CD25- CD4+ glucocorticoid-induced TNF receptor family-related gene+ regulatory T cells. J Immunol 2003, 171:708-716.
67. Suri A., Shimizu J., Katz J.D., Sakaguchi S., Unanue E.R., Kanagawa O. Regulation of autoimmune diabetes by non-islet-specific T cells-a role for the glucocorticoid-induced TNF receptor. Eur J Immunol 2004, 34:447-454.